ABT-263 (Navitoclax)

Catalog No.S1001

ABT-263 (Navitoclax) is a potent inhibitor of Bcl-xL, Bcl-2 and Bcl-w with Ki of ≤ 0.5 nM, ≤1 nM and ≤1 nM in cell-free assays, but binds more weakly to Mcl-1 and A1. Phase 2.

Price Stock Quantity  
USD 400 In stock
USD 120 In stock
USD 200 In stock
USD 370 In stock
USD 970 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

ABT-263 (Navitoclax) Chemical Structure

ABT-263 (Navitoclax) Chemical Structure
Molecular Weight: 974.61

Validation & Quality Control

Product Use Citation(35)

Customer Product Validation(13)

Quality Control & MSDS

Related Compound Libraries

ABT-263 (Navitoclax) is available in the following compound libraries:

Bcl-2 Inhibitors with Unique Features

  • Selective Bcl-2 Inhibitor

    ABT-199 (GDC-0199) Bcl-2-selective, Ki<0.01 nM.

  • Bcl-2 Inhibitor in Clinical Trial

    Obatoclax Mesylate (GX15-070) Phase II for leukemia, lymphoma, myelofibrosis, and mastocytosis.

  • Newest Bcl-2 Family Activator

    BAM7 Direct and selective activator of proapoptotic Bax with EC50 of 3.3 μM.

  • Classic Bcl-2 Inhibitor

    ABT-737 BH3-mimetic inhibitor, Bcl-xL, EC50=78.7 nM; Bcl-2, EC50=30.3 nM; Bcl-w, EC50=197.8 nM.

Product Information

  • Compare Bcl-2 Inhibitors
    Compare Bcl-2 Products
  • Research Area
  • Inhibition Profile

Product Description

Biological Activity

Description ABT-263 (Navitoclax) is a potent inhibitor of Bcl-xL, Bcl-2 and Bcl-w with Ki of ≤ 0.5 nM, ≤1 nM and ≤1 nM in cell-free assays, but binds more weakly to Mcl-1 and A1. Phase 2.
Targets Bcl-xL [1]
(Cell-free assay)
Bcl-2 [1]
(Cell-free assay)
Bcl-w [1]
(Cell-free assay)
A1 [1]
(Cell-free assay)
Mcl-1 [1]
(Cell-free assay)
IC50 <=0.5 nM(Ki) <=1 nM(Ki) <=1 nM(Ki) 354 nM(Ki) 550 nM(Ki)
In vitro ABT-263 is structurally related to ABT-737; it is a disruptor of Bcl-2/Bcl-xL interactions with pro-apoptotic proteins. Overexpression of the prosurvival Bcl-2 family members is commonly associated with tumor maintenance, progression, and chemoresistance. [1] ABT-263 displays the protection afforded by overexpression of Bcl-2 or Bcl-xL with EC50 values of 60 nM and 20 nM, respectively. [1] A wide range of cellular activity is observed with ABT-263 having a 50% growth inhibition (EC50) of 110 nM against the most sensitive line (H146), whereas its activity in the least sensitive line (H82) results in an EC50 at 22 μM. All four cell lines with EC50 values of <400 nM (H146, H889, H1963, and H1417) are also highly sensitive to ABT-737, and the two most resistant lines (H1048 and H82) are similarly resistant to ABT-263. [2]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
EoL-1-cellNHnpPIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGPoR2JKSzVyPUCuNFA3PjlizszNM4XBfXNCVkeHUh?=
MV-4-11MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIL6e|BKSzVyPUCuNFE2QDZizszNNVO5ZlJbW0GQR1XS
NKM-1NVywNHB5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NH2xPJZKSzVyPUCuNFE3QTlizszNNH\KUIJUSU6JRWK=
ML-2NGjHc3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHj4bYFKSzVyPUCuNFE6QDNizszNM4rjNnNCVkeHUh?=
BV-173NHTQelJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUPC[pduUUN3ME2wMlAzOzF2IN88US=>M3WwNXNCVkeHUh?=
RS4-11Ml7CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NV7zSJVGUUN3ME2wMlAzPTh5IN88US=>MYjTRW5ITVJ?
HL-60NH3I[HFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1rCTWlEPTB;MD6wNlkxQCEQvF2=NUS4dZR1W0GQR1XS
KY821M2POOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWfJR|UxRTBwMEK5O|Uh|ryPM{\MbXNCVkeHUh?=
ECC10MoHWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYTJR|UxRTBwMEO3PVIh|ryPMU\TRW5ITVJ?
NCI-H720MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NF3kToxKSzVyPUCuNFQxOTFizszNMYrTRW5ITVJ?
QIMR-WILMlnlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2Th[mlEPTB;MD6wOFI5PyEQvF2=NWH5[pV5W0GQR1XS
KG-1MkTCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIXiSotKSzVyPUCuNFQ1QDZizszNNV3zW2kxW0GQR1XS
TGWM4S4[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYj0PFFEUUN3ME2wMlA1PjN|IN88US=>NFnBZo5USU6JRWK=
ATN-1MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYPJR|UxRTBwMES3N|Mh|ryPMoO4V2FPT0WU
RH-18MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXvJR|UxRTBwME[wOFgh|ryPNGTaWIVUSU6JRWK=
EW-18NHzpfWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFL5PYdKSzVyPUCuNFY5PDFizszNM2jrbnNCVkeHUh?=
NB17MkjnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmTTTWM2OD1yLkC3NVI1KM7:TR?=NIrLe4JUSU6JRWK=
SK-NEP-1MnjwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NF[zelFKSzVyPUCuNFczOTNizszNMkW4V2FPT0WU
P12-ICHIKAWAMYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUXJR|UxRTBwMEe3O|gh|ryPNGDPe2NUSU6JRWK=
KARPAS-45M{TMOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEHZWWRKSzVyPUCuNFc5OTVizszNM{GzSXNCVkeHUh?=
EW-3MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3nD[WlEPTB;MD6wPFA2OyEQvF2=MXzTRW5ITVJ?
NB13MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4K0ZmlEPTB;MD6wPFIxOyEQvF2=NH3se2FUSU6JRWK=
NCI-H209NWLP[GhpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFu1dIZKSzVyPUCuNFg4ODRizszNNFvMUpNUSU6JRWK=
NCI-H1092M12zUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkPJTWM2OD1yLkGwNlc2KM7:TR?=NVTxUGh6W0GQR1XS
NH-12MmjkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{HJcGlEPTB;MD6xNFc1PCEQvF2=MVLTRW5ITVJ?
697M1TrbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoPzTWM2OD1yLkGwPFM6KM7:TR?=MkDTV2FPT0WU
KE-37NXTJOmRVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXrJR|UxRTBwMUGzO{DPxE1?MlrZV2FPT0WU
MOLT-4MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYTJR|UxRTBwMUWxOlkh|ryPM{\ZbnNCVkeHUh?=
CHP-134M3T1W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2qyWWlEPTB;MD6xOlMxPiEQvF2=NYfCN|VHW0GQR1XS
D-283MEDNGL4T4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{XkbmlEPTB;MD6xO|Y5PiEQvF2=NUPCSppjW0GQR1XS
LU-135NFWxR2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUX0WlFtUUN3ME2wMlE5PTV{IN88US=>NGjtXGNUSU6JRWK=
LU-134-ANYrle4xCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlOyTWM2OD1yLkG4OlcyKM7:TR?=NFPwcnFUSU6JRWK=
EM-2M1XtdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4X6NmlEPTB;MD6xPVkyQCEQvF2=MnrZV2FPT0WU
LU-139MmDwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIThT2VKSzVyPUCuNlA1QThizszNM3XiOXNCVkeHUh?=
ALL-POMom3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYXJR|UxRTBwMkG5PFgh|ryPNE\kNJZUSU6JRWK=
NB12NIrIfHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYXKWFdtUUN3ME2wMlI{OTF3IN88US=>NGTSNZJUSU6JRWK=
KP-N-YNNYLaOZJ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Ml;pTWM2OD1yLkKzOVc{KM7:TR?=MkfxV2FPT0WU
BENMU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEHLUllKSzVyPUCuNlM6PjhizszNMWrTRW5ITVJ?
HCC1569MljlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2S1bWlEPTB;MD6yOVExPiEQvF2=MnO1V2FPT0WU
HuO9NV7WTZFmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4fmVGlEPTB;MD6yOlcyPSEQvF2=NUHmcYIzW0GQR1XS
WM-115MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGDPeFlKSzVyPUCuNlc4OzhizszNMl:1V2FPT0WU
CCRF-CEMMYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXnJR|UxRTBwM{O1Nlkh|ryPM{PiPHNCVkeHUh?=
IST-SL1NFPVfFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmD0TWM2OD1yLkO1N|Q{KM7:TR?=Mk\yV2FPT0WU
BE-13NX64fGZxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoeyTWM2OD1yLkO2OFU6KM7:TR?=MonyV2FPT0WU
COR-L88NF7oblVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUfJR|UxRTBwM{[1OEDPxE1?NEK3VW9USU6JRWK=
DOHH-2MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFH5XI5KSzVyPUCuOFExOjNizszNNVG1Tpk3W0GQR1XS
A704NELn[YZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NH3JbHNKSzVyPUCuOFI3PyEQvF2=NHy5No9USU6JRWK=
KNS-81-FDM1K2d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlTrTWM2OD1yLkS0NFE4KM7:TR?=MUnTRW5ITVJ?
RPMI-8226NWHBSWJwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NILhNlRKSzVyPUCuOFU3PTJizszNMV\TRW5ITVJ?
TGBC24TKBMoDTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3LXVWlEPTB;MD60OVc4QCEQvF2=M{\hR3NCVkeHUh?=
NCI-H1304MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NX3RWJN6UUN3ME2wMlQ3OTV5IN88US=>MXfTRW5ITVJ?
MOLT-13NXjXbopET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFy3NZBKSzVyPUCuOFY3OTNizszNNYS5d2tuW0GQR1XS
EW-22NFq0V25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVrJNoc5UUN3ME2wMlQ3PjdzIN88US=>MVrTRW5ITVJ?
MS-1NWnXe4xbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3fRVmlEPTB;MD60Olk{OyEQvF2=MWLTRW5ITVJ?
RMG-IM3HmPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHvwS5RKSzVyPUCuOFk1PjRizszNMoHJV2FPT0WU
NTERA-S-cl-D1NELmbppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHPBOmZKSzVyPUCuOVAxOTlizszNM3rrOHNCVkeHUh?=
NCI-H1048M{LmUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NV;WOHRpUUN3ME2wMlUxQTV|IN88US=>NELqcmtUSU6JRWK=
SW1417MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Ml7GTWM2OD1yLkW1OFM5KM7:TR?=M2HlPHNCVkeHUh?=
DBMmjjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1y4VGlEPTB;MD61O|A5KM7:TR?=M1vy[3NCVkeHUh?=
MEG-01MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUPJR|UxRTBwNUizNkDPxE1?MV7TRW5ITVJ?
EW-13M{T0PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3\uZ2lEPTB;MD61PFM1OSEQvF2=MV3TRW5ITVJ?
LAMA-84M4nVVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmHXTWM2OD1yLkW5NlA4KM7:TR?=NGn2NItUSU6JRWK=
J-RT3-T3-5NVnhVGpWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUPkO293UUN3ME2wMlYxQDB6IN88US=>MWXTRW5ITVJ?
MOLT-16M1LRdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYTJR|UxRTBwNkWyOlQh|ryPMW\TRW5ITVJ?
DU-4475MlLwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mk\vTWM2OD1yLk[1OFI4KM7:TR?=MVXTRW5ITVJ?
HAL-01MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYDJR|UxRTBwN{K1OFkh|ryPM3W0RnNCVkeHUh?=
RDNGHEV2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVXJR|UxRTBwN{W4PVkh|ryPM4LuU3NCVkeHUh?=
OAW-28NIT1bJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoXPTWM2OD1yLke4N|ch|ryPNHPrWWNUSU6JRWK=
HCC38M2Hme2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWDj[IlEUUN3ME2wMlgxOTlizszNMoPnV2FPT0WU
NMC-G1MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1LDSGlEPTB;MD64NVEzOSEQvF2=NVqyeYZHW0GQR1XS
EW-16NELqdlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4\SWGlEPTB;MD64NVMzQCEQvF2=NEH4bmFUSU6JRWK=
DU-145NX:3fVFYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MojPTWM2OD1yLki5PVI{KM7:TR?=MkToV2FPT0WU
HPAF-IINE\mVFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlfHTWM2OD1yLkmyOlI5KM7:TR?=Ml;FV2FPT0WU
A427MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIL0O49KSzVyPUCuPVMxOjJizszNMkO5V2FPT0WU
PA-1NVPFOVdET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3qwbGlEPTB;MD65OVY1OiEQvF2=MVPTRW5ITVJ?
OAW-42MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mn\mTWM2OD1yLkm2NVQ3KM7:TR?=MX\TRW5ITVJ?
L-428NUPWWIR5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NH2ycnlKSzVyPUGuNFEzPSEQvF2=MYfTRW5ITVJ?
COLO-824MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEPTV4xKSzVyPUGuNFE4ODhizszNNVXQO5ZiW0GQR1XS
P30-OHKMYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{PDSmlEPTB;MT6wOFY5QCEQvF2=M13CbHNCVkeHUh?=
NCI-H2170NXfkXHA{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3zvRWlEPTB;MT6wOlI{KM7:TR?=NGC5R|lUSU6JRWK=
HCC2998NGTwUHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkDXTWM2OD1zLkC3NVM2KM7:TR?=MWjTRW5ITVJ?
NB14MoXNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXnJR|UxRTFwMUO3OFgh|ryPM1zJdHNCVkeHUh?=
TGBC1TKBNH\YXVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4rYPWlEPTB;MT6xOFE2OiEQvF2=MXvTRW5ITVJ?
KP-N-YSM4P6Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NF7EXJJKSzVyPUGuNVYzOzZizszNMYLTRW5ITVJ?
CAL-120NWTIWGNJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3HHPWlEPTB;MT6xOlQzQSEQvF2=MUPTRW5ITVJ?
SBC-1MkLmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M331V2lEPTB;MT6xPVA2OyEQvF2=MYjTRW5ITVJ?
C32NX;6bFF2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVfJR|UxRTFwMUmwPFgh|ryPM4TQcnNCVkeHUh?=
HCC2157M4rWdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYDwVWlWUUN3ME2xMlE6PDl2IN88US=>Mo\LV2FPT0WU
COLO-792M3;iRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXTxS5d6UUN3ME2xMlIxODdzIN88US=>NYHVUY9PW0GQR1XS
ES7MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1r1emlEPTB;MT6yO|k2OSEQvF2=M3rFeHNCVkeHUh?=
HELMl7qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnjMTWM2OD1zLkOxNFI6KM7:TR?=M33LdnNCVkeHUh?=
ES4NIfvSGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MX;JR|UxRTFwM{S5PVgh|ryPM{j4enNCVkeHUh?=
NCI-SNU-1MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1LWOGlEPTB;MT6zOlU2PSEQvF2=NHLUfIpUSU6JRWK=
MDA-MB-415MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1rsOWlEPTB;MT6zPFg2KM7:TR?=NX:1WmpOW0GQR1XS
NCI-H2342M4LQTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4nCemlEPTB;MT60NFI3QSEQvF2=NE\DUVJUSU6JRWK=
NB69NHz6enBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3;wRWlEPTB;MT60OlI4OSEQvF2=MmTFV2FPT0WU
D-247MGNVv5N3lZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlGyTWM2OD1zLkWxNVIzKM7:TR?=NUTX[2tIW0GQR1XS
SCC-4M1fFTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUHJR|UxRTFwNUm4PFch|ryPM1;aU3NCVkeHUh?=
HuH-7M17zUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2rHcmlEPTB;MT62O|I6OyEQvF2=NF3hd4FUSU6JRWK=
A388NWXEOphmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlK5TWM2OD1zLk[4O|I1KM7:TR?=MlfYV2FPT0WU
Calu-3MmHSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4HBUGlEPTB;MT63NFY6PyEQvF2=NXvLd4gzW0GQR1XS
NCI-H1648MnHQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnfpTWM2OD1zLkexOFE5KM7:TR?=MoTaV2FPT0WU
NCI-H2052MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVLz[4l{UUN3ME2xMlczOjBzIN88US=>MXvTRW5ITVJ?
Ramos-2G6-4C10NV24OWx{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3TBdmlEPTB;MT63N|Y2PiEQvF2=MXTTRW5ITVJ?
DELM3TrZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mk\6TWM2OD1zLke0OlkzKM7:TR?=MojXV2FPT0WU
SNU-423NY\xeZZVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYjrSW1qUUN3ME2xMlc5OTV5IN88US=>NH;5fGpUSU6JRWK=
COR-L23M2D5cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3r5R2lEPTB;MT63PVg4PCEQvF2=Mm\ZV2FPT0WU
OMC-1M1\xVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGrzfoZKSzVyPUGuPFYxOTZizszNNUDWZ5RvW0GQR1XS
EW-11NIP6Um1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4rIVmlEPTB;MT65OVY2PyEQvF2=M4f0NnNCVkeHUh?=
HSC-3NXPNWINuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUjJR|UxRTFwOU[zOlUh|ryPMYrTRW5ITVJ?
MLMAMXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MX;JR|UxRTFwOU[2O|ch|ryPNHjlNItUSU6JRWK=
RCM-1MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4K3c2lEPTB;Mj6wNFM6QSEQvF2=NUG1Z29rW0GQR1XS
MFE-280MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYHJR|UxRTJwMEK4OFgh|ryPMmPIV2FPT0WU
ES8MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkmwTWM2OD1{LkK1OFcyKM7:TR?=M3yzbnNCVkeHUh?=
TE-11NEW5UnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVKxfppIUUN3ME2yMlI6PDd|IN88US=>Mn;EV2FPT0WU
HuO-3N1MkHSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NE\YdYpKSzVyPUKuOFg4QCEQvF2=MWfTRW5ITVJ?
MHH-NB-11Mo[xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlGwTWM2OD1{LkWxNVU5KM7:TR?=NInweJhUSU6JRWK=
TGBC11TKBNWK4fJd[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXXyelV5UUN3ME2yMlU4PjhzIN88US=>MkXHV2FPT0WU
HOP-92M1HvNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYXJR|UxRTJwNUi3OFMh|ryPMVLTRW5ITVJ?
IGR-1M4Swd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVX5[JJpUUN3ME2yMlYzODN3IN88US=>M3;VVnNCVkeHUh?=
GOTOMXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWLJR|UxRTJwNkWzO|ch|ryPM2nJRXNCVkeHUh?=
NCI-H1650MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1X4XWlEPTB;Mj63NlIyPSEQvF2=MV7TRW5ITVJ?
NCI-H1581Ml7zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1\YdWlEPTB;Mj63PVY5OSEQvF2=MoDKV2FPT0WU
NCI-H2405M1LFUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXP4VFV1UUN3ME2yMlgzPzh{IN88US=>MUPTRW5ITVJ?
U-118-MGM4H1VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NE\aTFlKSzVyPUKuPVY1QTFizszNMX;TRW5ITVJ?
DoTc2-4510NE\J[XdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlfLTWM2OD1|LkCxOFE4KM7:TR?=M2X5[HNCVkeHUh?=
NCI-H596MoHwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIP2XlJKSzVyPUOuNFQ6QTdizszNMlHhV2FPT0WU
MPP-89NFXwWlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVvJR|UxRTNwMEW2OlYh|ryPM1nibHNCVkeHUh?=
GCIYMX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXrTVnJ5UUN3ME2zMlIxPDlzIN88US=>MlnxV2FPT0WU
SW626M2XFbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NG\SdIFKSzVyPUOuNlQ2PDNizszNMWjTRW5ITVJ?
OCI-AML2MonhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{TsV2lEPTB;Mz6zNVI4OiEQvF2=MmnyV2FPT0WU
NBsusSRMWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHP5bXNKSzVyPUOuN|Q6OzhizszNMYjTRW5ITVJ?
AN3-CAMoKwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2SzOmlEPTB;Mz60OFI{QCEQvF2=MU\TRW5ITVJ?
EFM-19NH7sdphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWjvN3JpUUN3ME2zMlQ5OzN7IN88US=>M4jLSHNCVkeHUh?=
RVH-421M2jy[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NF3nRnNKSzVyPUOuOVY5PzdizszNNHzpbFlUSU6JRWK=
5637NVLmdoJ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVKydlI2UUN3ME2zMlYyOTB|IN88US=>MXrTRW5ITVJ?
PANC-08-13MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnS0TWM2OD1|Lk[zOFczKM7:TR?=Ml70V2FPT0WU
H9M4T4UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3PFZ2lEPTB;Mz62O|E1PCEQvF2=MkP1V2FPT0WU
KARPAS-299NHL0RnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3rTTmlEPTB;Mz62O|M3OSEQvF2=NF3Yc25USU6JRWK=
TE-5MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXPJR|UxRTNwN{C3NFkh|ryPNXTPbGNvW0GQR1XS
NOS-1MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mn7tTWM2OD1|Lke5PFM1KM7:TR?=Mo\RV2FPT0WU
HHMlPhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mkj1TWM2OD1|LkizPFY5KM7:TR?=NWPDfmZuW0GQR1XS
769-PM{HTXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkS2TWM2OD1|Lki5OVEh|ryPNFLNNG1USU6JRWK=
CHP-212Mlz0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1X0O2lEPTB;Mz65NlU1QSEQvF2=NFXBdHhUSU6JRWK=
NCI-H82MoX5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVjJR|UxRTNwOUW5N|Yh|ryPMX;TRW5ITVJ?
Mo-TMlLLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXTJR|UxRTRwMESzNVIh|ryPNWPUNHRMW0GQR1XS
BB65-RCCMYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWrJR|UxRTRwMESzPVkh|ryPNUWxR2JCW0GQR1XS
SW1990NVTmfJZFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2H5[WlEPTB;ND6wOVkxQCEQvF2=M3jtVnNCVkeHUh?=
LK-2NFXpPXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYXJR|UxRTRwMUGyPVMh|ryPMk\yV2FPT0WU
ES5NXPzTmZRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NF3ueZRKSzVyPUSuNVM6QDVizszNMULTRW5ITVJ?
JVM-3NWLuc3o5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIS5ZmJKSzVyPUSuNVgzOjJizszNNIDIc2pUSU6JRWK=
RPMI-7951M4LHdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnPITWM2OD12LkKyOFE{KM7:TR?=MkXzV2FPT0WU
Calu-6NX\VT2I4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkLYTWM2OD12LkK3PFgyKM7:TR?=M3zuTXNCVkeHUh?=
LC-2-adNGDLRYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUHJR|UxRTRwMkm1Olgh|ryPNHvVcXJUSU6JRWK=
SW954MlLRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVvzRXBQUUN3ME20MlI6PjZizszNNWq5T5NlW0GQR1XS
H-EMC-SSNVPXSpV5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlnuTWM2OD12LkOxPFMyKM7:TR?=M1nJcnNCVkeHUh?=
ES3NW[0UGZtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVfJR|UxRTRwM{W0OFEh|ryPM1PlXXNCVkeHUh?=
no-11M4X5cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVrJR|UxRTRwM{W1OVQh|ryPNYDtd2s2W0GQR1XS
LAN-6M1jE[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXe5N|cxUUN3ME20MlQ2OTh7IN88US=>NHvpb49USU6JRWK=
FTC-133NGrYboVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mkf3TWM2OD12LkWzPVUh|ryPMVHTRW5ITVJ?
8505CNYK1blFYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkHiTWM2OD12LkW0NlMh|ryPMl\UV2FPT0WU
SW620NEe5UVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXHJR|UxRTRwNUewOVch|ryPNV;IUpRsW0GQR1XS
BCPAPMnqxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWDCNZNYUUN3ME20MlY{PDhzIN88US=>M3:3UnNCVkeHUh?=
SK-LU-1M1;3fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MX3JR|UxRTRwNk[wPFkh|ryPM1WzXnNCVkeHUh?=
NCI-H1623NHH3XZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M13ScmlEPTB;ND63NFIzQCEQvF2=MUTTRW5ITVJ?
C2BBe1NYr0eZhsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3vH[2lEPTB;ND63OFAxQCEQvF2=MYXTRW5ITVJ?
GP5dMoPzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXrJR|UxRTRwN{izPFgh|ryPM33KO3NCVkeHUh?=
NB6M4fze2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUPJR|UxRTRwOE[yNFQh|ryPNGnkTHJUSU6JRWK=
MDA-MB-157M{DWPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXXJR|UxRTRwOEi3OkDPxE1?MXXTRW5ITVJ?
UMC-11NFj3clVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4\MfGlEPTB;ND64PFk3PCEQvF2=MYfTRW5ITVJ?
HCC1419MmDIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnzXTWM2OD12LkmwNFY{KM7:TR?=MX\TRW5ITVJ?
NCI-H2029NILHd45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3e3dGlEPTB;ND65OFE5PSEQvF2=NEnsSmhUSU6JRWK=
LXF-289M3O3TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYjJR|UxRTVwMEO3NVkh|ryPNFHsXZBUSU6JRWK=
KINGS-1MlPOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnnaTWM2OD13LkC3O|Q1KM7:TR?=NWi2R2p7W0GQR1XS
HD-MY-ZMVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYnJR|UxRTVwMkO5Olkh|ryPNYjTR21jW0GQR1XS
ESS-1M1n5OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYnJR|UxRTVwMkW1PVch|ryPMoPYV2FPT0WU
GI-1NHXOdnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnX1TWM2OD13LkK3PVI3KM7:TR?=MlvlV2FPT0WU
RPMI-2650M3\Kcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWrJR|UxRTVwM{[xOkDPxE1?MYHTRW5ITVJ?
IA-LMNFi4cIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MX;JR|UxRTVwM{m4O|Eh|ryPM3nIOHNCVkeHUh?=
KP-4NWLk[m9zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mk[xTWM2OD13LkS2N|M1KM7:TR?=NWSxSW5kW0GQR1XS
G-402M1Pa[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVPJR|UxRTVwNUG4OlUh|ryPMmrWV2FPT0WU
OS-RC-2M{TUcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NW\MNmhPUUN3ME21MlUzPjB2IN88US=>MXzTRW5ITVJ?
NCI-H1155M2fUTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4DyTWlEPTB;NT61OFk2PSEQvF2=NI[zV2hUSU6JRWK=
OE19M4\6ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4nGZmlEPTB;NT62PFYzPCEQvF2=NXL4ZmZiW0GQR1XS
U-2-OSNHvRNZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlLWTWM2OD13Lki5NFE{KM7:TR?=NVO1fJFuW0GQR1XS
SCC-15MnHhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1nLZWlEPTB;NT65N|Y3OiEQvF2=NWLjd5oxW0GQR1XS
NCI-H630MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkO3TWM2OD13Lkm5OFA1KM7:TR?=NUf5NogyW0GQR1XS
PFSK-1NXe3UpRkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmfDTWM2OD14LkC1NlU6KM7:TR?=M2TZXnNCVkeHUh?=
NCI-H1770NWrEe5U4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVXJR|UxRTZwMkC4O|Qh|ryPMXHTRW5ITVJ?
SK-MEL-3NXLTVplqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4facWlEPTB;Nj60NlkyPSEQvF2=M1KzPXNCVkeHUh?=
LB1047-RCCMljRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlvnTWM2OD14LkS3OlI2KM7:TR?=NIfPNYVUSU6JRWK=
NCI-H446NHjRe5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWHJR|UxRTZwNkK5NlUh|ryPNVnXeVFNW0GQR1XS
SW780NIfScZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWPJR|UxRTZwN{CxPFUh|ryPNX;4[nU3W0GQR1XS
NEC8NFPoSHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlzxTWM2OD14Lke2OlMh|ryPM3LkSnNCVkeHUh?=
NOMO-1NH;pcnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWPJR|UxRTZwN{ixNVEh|ryPNG\mfI1USU6JRWK=
COLO-668MnjVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnrjTWM2OD14Lki0N|g4KM7:TR?=NYrWO3ZwW0GQR1XS
MC116M4jSeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVmwfnllUUN3ME22Mlk{QDl5IN88US=>MWTTRW5ITVJ?
HCC1937M{jGSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYHJR|UxRTZwOUmyOVEh|ryPM2\XcHNCVkeHUh?=
NCI-N87NYT5foQ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MW\JR|UxRTdwMUmyPVMh|ryPMnHHV2FPT0WU
COLO-320-HSRM2nsWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXHJR|UxRTdwMkK3N|gh|ryPM37oe3NCVkeHUh?=
HCC1806MlzXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUjZd2xvUUN3ME23MlI3ODR2IN88US=>M3zNd3NCVkeHUh?=
OVCAR-3M2DTV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVnJR|UxRTdwM{OwN|gh|ryPNXXmXGZCW0GQR1XS
NUGC-3M{TKNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MX;JR|UxRTdwM{m2PVQh|ryPNV22[XpYW0GQR1XS
SW1783NIDjOmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlmzTWM2OD15LkSzNVc2KM7:TR?=Ml;pV2FPT0WU
GCTNVHhXWZyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXnJR|UxRTdwNU[5NFYh|ryPNUjuOIdPW0GQR1XS
NCI-H2126MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mn[zTWM2OD15LkezOlI2KM7:TR?=MV3TRW5ITVJ?
MEL-HOMVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYrJR|UxRTdwN{ewOVQh|ryPNGriNohUSU6JRWK=
CAPAN-1M174N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mm\RTWM2OD15Lke3N|U4KM7:TR?=MVHTRW5ITVJ?
SW756M2jOeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlrkTWM2OD15Lke4N|M{KM7:TR?=M4LCR3NCVkeHUh?=
SKG-IIIaM3[xbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{LuVGlEPTB;Nz64NVg6OiEQvF2=M37kS3NCVkeHUh?=
HCE-TNVP6UFdKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFjvWWZKSzVyPUeuPFc4QDNizszNMkDwV2FPT0WU
Ca-SkiNX;FTXRjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVu4fWs5UUN3ME23Mlk6Ozh|IN88US=>MnT5V2FPT0WU
COLO-684M3\zWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4\QNmlEPTB;OD6wNVgyQCEQvF2=NHHEdmNUSU6JRWK=
KYSE-70Mo\zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXPJR|UxRThwMEe3Nlkh|ryPMYjTRW5ITVJ?
TI-73NUHhN|BkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYDJR|UxRThwMkW4OVEh|ryPNX[yPZdoW0GQR1XS
BT-20MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1jCfmlEPTB;OD6yOlA2OiEQvF2=MYjTRW5ITVJ?
MHH-ES-1NFewcIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NInNUoVKSzVyPUiuOVE5OzRizszNNXr2cW5OW0GQR1XS
TE-12NE\IenVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3GwOWlEPTB;OD61PVk{OSEQvF2=M4Xj[nNCVkeHUh?=
YH-13M3O5OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWjJR|UxRThwNkGwNFgh|ryPNIjDelJUSU6JRWK=
SF126MnPVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NX;0b2RWUUN3ME24Mlg{QDZ3IN88US=>Ml30V2FPT0WU
J82M3nmSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1;lTGlEPTB;OD65NFA{QCEQvF2=NGDoe3pUSU6JRWK=
RCC10RGBNG\KcGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NF3oTmhKSzVyPUiuPVk2PjFizszNMkKzV2FPT0WU
SK-UT-1M3XnSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mk\mTWM2OD17LkC0PVQ2KM7:TR?=MYrTRW5ITVJ?
LB2241-RCCNYXrcYc1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NF3mc4hKSzVyPUmuNVkyOzdizszNMlTIV2FPT0WU
LB996-RCCNFPw[oVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MV7JR|UxRTlwMUm4PUDPxE1?NG\qZnNUSU6JRWK=
EPLC-272HMWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NF\KcpFKSzVyPUmuN|c3PTdizszNNFK3cXBUSU6JRWK=
CTV-1M{\I[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFvTNIZKSzVyPUmuOVY2OzJizszNNXOzOVlTW0GQR1XS
HSC-2M4LzNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MX;JR|UxRTlwNUe1OUDPxE1?NVLvTm5XW0GQR1XS
SK-MEL-28NHKxRXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUjJR|UxRTlwNkG4PVMh|ryPMoPFV2FPT0WU
MMAC-SFNF;4[olIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3\DbWlEPTB;OT62PFc2KM7:TR?=MVrTRW5ITVJ?
CP50-MEL-BMkjkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFfYcmdKSzVyPUmuO|U4QDJizszNMlTCV2FPT0WU
HT-1080NGnmXIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHK3Wm5KSzVyPUmuO|c4OzlizszNNWj1VmdQW0GQR1XS
HEC-1NUTuXZNPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnPQTWM2OD1zMD6zN|UzKM7:TR?=NFHzbJpUSU6JRWK=
AGSMlXNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIm5fpFKSzVyPUGwMlM4PCEQvF2=NWHu[|BPW0GQR1XS
GAMGNIG3ZYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVLJR|UxRTFyLkWxOlIh|ryPNYG2XFlGW0GQR1XS
SW48MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVzJR|UxRTFyLkWxPFkh|ryPM1zDPHNCVkeHUh?=
U031NGP1OmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXrJR|UxRTFyLkW5NFgh|ryPMV\TRW5ITVJ?
OVCAR-5NF\qfpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFHhXZVKSzVyPUGwMlY1OjlizszNMnLuV2FPT0WU
SF295MkPiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVLZWFA6UUN3ME2xNE43PzB2IN88US=>M1i5UnNCVkeHUh?=
BHT-101M1X2TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIHENWJKSzVyPUGwMlcyPzdizszNMn[3V2FPT0WU
VMRC-RCZM3H1fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MX3JR|UxRTFzLkOyNFEh|ryPM{Tn[HNCVkeHUh?=
ACHNNFn6[phIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFXobGhKSzVyPUGxMlQzOTFizszNMUDTRW5ITVJ?
NCI-H526NHHUWo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkP6TWM2OD1zMT61NFQ{KM7:TR?=MXXTRW5ITVJ?
MN-60MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXvDR5ZsUUN3ME2xNU42OzlizszNMln3V2FPT0WU
NCI-H2291M4LSZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWPuOGlbUUN3ME2xNU42PDZ4IN88US=>NF\aWVRUSU6JRWK=
SCC-25MlHpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHPuXXRKSzVyPUGxMlc2PTZizszNNWTCN2NvW0GQR1XS
SK-MEL-2NX\5Onl7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYXJR|UxRTFzLke2N|ch|ryPMX;TRW5ITVJ?
SN12CNGHyTIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3jwOGlEPTB;MUGuPVM2PSEQvF2=MYHTRW5ITVJ?
NCI-H69NXLnV45HT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4XDZmlEPTB;MUKuOFI{PCEQvF2=NH;KbpBUSU6JRWK=
ME-180MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYX3NFI{UUN3ME2xNk44ODV2IN88US=>MV\TRW5ITVJ?
MC-IXCMmPsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVPJR|UxRTF{Lke1NVgh|ryPMYTTRW5ITVJ?
NCI-H2347MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVLJR|UxRTF{Lke2NVQh|ryPMVPTRW5ITVJ?
M059JMo\SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mnf1TWM2OD1zMj63O|I4KM7:TR?=NWS1SYVjW0GQR1XS
A2058MkLLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFTvSWlKSzVyPUGyMlg3QDFizszNNYDETotlW0GQR1XS
VA-ES-BJMmXTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3S4NGlEPTB;MUKuPFc5PSEQvF2=NFzGXI5USU6JRWK=
Ca9-22MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkH2TWM2OD1zMj65OFUyKM7:TR?=NV3UTmFMW0GQR1XS
KNS-42M2T2VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGTxcVFKSzVyPUGyMlk6QDRizszNMoK3V2FPT0WU
LoVoMV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmHQTWM2OD1zMz6yN|E{KM7:TR?=M3nrN3NCVkeHUh?=
AM-38MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmS2TWM2OD1zMz6yOVY3KM7:TR?=NHnSNWdUSU6JRWK=
NB5MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MX3JR|UxRTF|LkO3OVIh|ryPNHroVXJUSU6JRWK=
L-363NFn4PJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlLyTWM2OD1zMz60NFM{KM7:TR?=NX3LUIZzW0GQR1XS
SK-MEL-30NIi0ZpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUC3OFNlUUN3ME2xOE4xPjR3IN88US=>NX7JOYNlW0GQR1XS
NCI-H1563NUXqcFQzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVrOV3NKUUN3ME2xOE43ODN7IN88US=>NXu0[4VNW0GQR1XS
NCI-H2228MmmyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{T2NmlEPTB;MUSuOlA4PyEQvF2=MYjTRW5ITVJ?
MFM-223MknpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4fZZmlEPTB;MUWuNVgyOyEQvF2=NFXBcFVUSU6JRWK=
LB831-BLCMnrkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1jPdWlEPTB;MUWuNlc3PyEQvF2=NYq4XmlrW0GQR1XS
SW872MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoLQTWM2OD1zNT6zNFg3KM7:TR?=MULTRW5ITVJ?
NCI-H522NUHIXoc1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXTmZpJZUUN3ME2xOU4{OzB4IN88US=>M1naNXNCVkeHUh?=
EW-1M4LyeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIjYWmZKSzVyPUG1MlU1PjJizszNMmmzV2FPT0WU
HNNWDHUXV7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2DuWWlEPTB;MUWuOVk1OiEQvF2=NILLU5dUSU6JRWK=
SW837M{Pnfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHnUbWtKSzVyPUG1Mlc5PDdizszNMlHiV2FPT0WU
SCC-9NHTBR4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmfKTWM2OD1zNT64NVE1KM7:TR?=MVfTRW5ITVJ?
MKN7MoXhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEWxUJdKSzVyPUG1Mlk4OzJizszNNYTucHI6W0GQR1XS
KYSE-410MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4\yN2lEPTB;MU[uOVkyKM7:TR?=M1H3OnNCVkeHUh?=
SK-N-DZMmHVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MW\JR|UxRTF4Lk[xNVYh|ryPM1XSRnNCVkeHUh?=
COR-L105NVrzUlNvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXnKUFJSUUN3ME2xOk43PTJ6IN88US=>M{PKO3NCVkeHUh?=
LB2518-MELNIfHd45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoP4TWM2OD1zNj64N|g6KM7:TR?=NW\4cW5MW0GQR1XS
OVCAR-4NUHudnRxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUfC[IRYUUN3ME2xOk45QDZ{IN88US=>M2XYbHNCVkeHUh?=
TK10NV3oeVlVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFjBTnJKSzVyPUG2Mlk1PzNizszNMn;OV2FPT0WU
KNS-62MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlP4TWM2OD1zNj65O|c4KM7:TR?=Ml3UV2FPT0WU
RPMI-8866MmDzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWPTe5JZUUN3ME2xO{4yPzN{IN88US=>NUTqVox4W0GQR1XS
HuP-T4M2PUNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEfuU3JKSzVyPUG3MlI1QTVizszNNWWzblVjW0GQR1XS
CGTH-W-1NGfveIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NETPRpZKSzVyPUG3MlUzOTlizszNMXPTRW5ITVJ?
T-24MnPXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Ml7ITWM2OD1zNz61N|Q4KM7:TR?=MYfTRW5ITVJ?
HT-3MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEjWWYxKSzVyPUG3MlU6OTRizszNNHy2R4tUSU6JRWK=
KS-1NXrMco9uT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWPJR|UxRTF5Lk[3N{DPxE1?NULqdIdtW0GQR1XS
NCI-H1792NIDrRoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWHqWW5yUUN3ME2xO{44QThizszNNH;WOYNUSU6JRWK=
ABC-1MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1nWOGlEPTB;MUeuPFE1OSEQvF2=NGe5e2hUSU6JRWK=
BPH-1M2\BNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYq4PWZ[UUN3ME2xPE4yPjh3IN88US=>NY\Qb25EW0GQR1XS
A431M4LJVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mk\3TWM2OD1zOD60NVI4KM7:TR?=NFrDe2RUSU6JRWK=
T98GNHXVbXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHWydVRKSzVyPUG4MlUyPTdizszNNFzx[IhUSU6JRWK=
BHYM2fIT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MV;JR|UxRTF6Lki2PUDPxE1?MUXTRW5ITVJ?
Capan-2M1:4O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGH5fWJKSzVyPUG4MlkxPzhizszNNEjCeIdUSU6JRWK=
MDA-MB-175-VIIMXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Ml\ZTWM2OD1zOD65NlA6KM7:TR?=MmTZV2FPT0WU
CAL-27NYPqNYlTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIW0b4JKSzVyPUG5MlA1QDdizszNM4j0XXNCVkeHUh?=
AsPC-1MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4jBNWlEPTB;MUmuPFY2PyEQvF2=MXnTRW5ITVJ?
KU812M1zEPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnfITWM2OD1zOT65OVc{KM7:TR?=MmPwV2FPT0WU
NCI-H441MnG4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXzyUmNJUUN3ME2yNE4xODFizszNNGHMVnRUSU6JRWK=
MewoMl3ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4nZVWlEPTB;MkCuNVI5QCEQvF2=NU\EXJZ2W0GQR1XS
SK-MEL-24MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4X0OWlEPTB;MkCuNVQ4PyEQvF2=NVTJSmdSW0GQR1XS
NCI-H727MnHYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVn4OVQ5UUN3ME2yNE4zPzB2IN88US=>MYPTRW5ITVJ?
EKVXMVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NH;4PVBKSzVyPUKwMlYxPiEQvF2=NEjlXVZUSU6JRWK=
RT-112MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIHkOodKSzVyPUKwMlYyOjJizszNMmLzV2FPT0WU
CAMA-1M2H2Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MULJR|UxRTJyLkm4NFMh|ryPNEHxemtUSU6JRWK=
SW900NU[xfmNQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmP6TWM2OD1{MT6wNVQ6KM7:TR?=NV7RTVNKW0GQR1XS
NCI-H23MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVrJR|UxRTJzLkGyO|ch|ryPM1npe3NCVkeHUh?=
SK-PN-DWM1;0XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3j0fmlEPTB;MkGuNVY1QSEQvF2=NVz1boQ6W0GQR1XS
BB30-HNCNH7wbZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWW0U5czUUN3ME2yNU4zPzR3IN88US=>MVjTRW5ITVJ?
VM-CUB-1MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2\PPGlEPTB;MkGuN|U{PiEQvF2=MUjTRW5ITVJ?
IST-MEL1M3PxeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4PCSmlEPTB;MkGuN|Y6OiEQvF2=NIKzfpBUSU6JRWK=
CTB-1MnjLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NX[4[ZdSUUN3ME2yNU41PzV3IN88US=>NWT1V3NlW0GQR1XS
LCLC-103HM{myUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M16weWlEPTB;MkKuNVU5OiEQvF2=MknuV2FPT0WU
PANC-03-27NIO1WnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NInaS4VKSzVyPUKyMlUyPjlizszNNFju[W1USU6JRWK=
HTC-C3NIO1eW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2LLcmlEPTB;MkKuOVU2PSEQvF2=NIfnT4RUSU6JRWK=
TE-8NVj0ZmFJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVPQPHRrUUN3ME2yN{4zPTZ3IN88US=>M4L0fHNCVkeHUh?=
NCI-H292NX[yVXVPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmrwTWM2OD1{NT6zOVM3KM7:TR?=NXLicFI4W0GQR1XS
COLO-680NNXvkeYRtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NE\qOXhKSzVyPUK1MlY{OjlizszNMlXnV2FPT0WU
KYSE-520MnTmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXHJR|UxRTJ3Lk[0OEDPxE1?NITKe4pUSU6JRWK=
NB10M3PiPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEjuSmpKSzVyPUK2MlMyOTdizszNNH;r[pVUSU6JRWK=
NCI-H661MkXuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYPJR|UxRTJ4LkS3NVMh|ryPMXjTRW5ITVJ?
GMS-10NEDRUmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYfJR|UxRTJ4Lki2N|gh|ryPNV7HRWtKW0GQR1XS
NCI-H2122NITOR5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWGwPVE1UUN3ME2yOk46QTl6IN88US=>M3nTSnNCVkeHUh?=
OVCAR-8NIDZS5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3PxemlEPTB;MkeuNFY{QCEQvF2=NHPzWFJUSU6JRWK=
DJM-1MlixS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUPJR|UxRTJ5LkG0OVQh|ryPM1TGUXNCVkeHUh?=
UACC-893M{TlWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4XMcWlEPTB;MkeuPVg4QCEQvF2=NGflZVZUSU6JRWK=
C8166NUHaR25JT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEnxZ5lKSzVyPUK4MlY6OzhizszNMX3TRW5ITVJ?
NCI-H1693Mo\VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXLJR|UxRTJ6Lk[5O|Uh|ryPNVH6W2luW0GQR1XS
TYK-nuMY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFW3N4JKSzVyPUOwMlA{PDVizszNMlLvV2FPT0WU
SW1710MljjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUfIWoxzUUN3ME2zNE4yOjZizszNMnXHV2FPT0WU
A375NYS4SJBOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWnsVHI1UUN3ME2zNE4{OjR|IN88US=>MVvTRW5ITVJ?
HMV-IINEjvfINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHfvbpZKSzVyPUOxMlM2QTJizszNNGLjVJZUSU6JRWK=
NCI-H2087M3;POWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmS5TWM2OD1|MT62N|UzKM7:TR?=NW\2bY5GW0GQR1XS
CAL-54M1v0eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUTJR|UxRTNzLkeyOFEh|ryPMULTRW5ITVJ?
HCC70MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWTVUlY2UUN3ME2zNk4yOzh5IN88US=>MVjTRW5ITVJ?
ES1Mn[wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIDVSFRKSzVyPUOyMlMxPjJizszNM1rZTXNCVkeHUh?=
NCI-H1355M3y1d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEjoVlhKSzVyPUOzMlIxPCEQvF2=NFHjXppUSU6JRWK=
CFPAC-1NFKwVW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3vv[2lEPTB;M{OuNlM{OiEQvF2=NIDZS2lUSU6JRWK=
MKN28NInwOWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkfvTWM2OD1|Mz6zPFA6KM7:TR?=MkLHV2FPT0WU
HDLM-2M2jrNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXvvUowzUUN3ME2zN{43QTNzIN88US=>M{LGNXNCVkeHUh?=
PANC-10-05M2D2OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXLJR|UxRTN2LkGwNVQh|ryPNVXyOlE3W0GQR1XS
SASNYDLNHgyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NH:zPWxKSzVyPUO0MlQ2PjVizszNM{XEe3NCVkeHUh?=
HCC1395Mn3GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3r4U2lEPTB;M{SuO|E5PiEQvF2=MYfTRW5ITVJ?
8305CM3zBd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mn6wTWM2OD1|NT64OFE2KM7:TR?=NWn6foVJW0GQR1XS
KM12MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{\2fGlEPTB;M{[uO|U1PyEQvF2=MVTTRW5ITVJ?
SW1116NHmycphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEW4UYdKSzVyPUO3MlU6QTJizszNNXTuRYlMW0GQR1XS
SK-MEL-1M1PqXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mk\lTWM2OD1|OD6zN|g6KM7:TR?=MoLhV2FPT0WU
HCC2218NEj0[|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mnn1TWM2OD1|OD62OVE6KM7:TR?=NHq2ZVZUSU6JRWK=
T84NF7tblBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NG\LUJZKSzVyPUO4Mlc1ODlizszNMX3TRW5ITVJ?
ETK-1MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGjseHJKSzVyPUO5MlAzOiEQvF2=NW\3eVhkW0GQR1XS
COLO-800MlG3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{Sx[mlEPTB;M{muN|g3QCEQvF2=NXW1bmM{W0GQR1XS
CAL-12TMWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHPtdJFKSzVyPUO5MlUzQDFizszNMmrzV2FPT0WU
ACNMoDPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkH2TWM2OD12MD60PVEyKM7:TR?=NIjkXllUSU6JRWK=
SJSA-1MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFP2cmpKSzVyPUSxMlE2QTZizszNNYnSZVVtW0GQR1XS
PSN1M4q4RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUDGNHZCUUN3ME20NU4yPzR7IN88US=>M2rPbXNCVkeHUh?=
D-566MGMVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1vFWWlEPTB;NEGuNlA5PiEQvF2=Mn\2V2FPT0WU
EGI-1MnvoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Moi5TWM2OD12Mj60Nlgh|ryPMl\PV2FPT0WU
A204NF3GPVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWXsSGZSUUN3ME20Nk43Ozh6IN88US=>M{DwRnNCVkeHUh?=
Saos-2MkLGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MX7JR|UxRTR{LkizOlkh|ryPM3SwfXNCVkeHUh?=
SNU-C2BNFHRWZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXy3ToxCUUN3ME20N{43QDd6IN88US=>NH3JNHJUSU6JRWK=
HLEMV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MV\JR|UxRTR2LkC4OVYh|ryPMkewV2FPT0WU
SW1463NW\m[Ip5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFHyTZFKSzVyPUS0Mlk6PzFizszNMXfTRW5ITVJ?
DSH1MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWDJR|UxRTR3LkCwN|Mh|ryPNF\OcmpUSU6JRWK=
MCF7NX32ToRvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFz2fYdKSzVyPUS1MlUxPTFizszNM{nUTnNCVkeHUh?=
K5NG\meI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoDPTWM2OD12NT65OFA2KM7:TR?=MWrTRW5ITVJ?
NCI-H358M3;vPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGnRTlVKSzVyPUS3MlIyPSEQvF2=MWnTRW5ITVJ?
NCI-H2030NF\IN21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3r1NGlEPTB;NEeuNlM4PCEQvF2=NFvDW2dUSU6JRWK=
SW948NYj3WFczT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWHjUIxjUUN3ME20O{41PjRizszNMYTTRW5ITVJ?
BALL-1MoWwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3rkdWlEPTB;NEeuOlE3QCEQvF2=MUDTRW5ITVJ?
TE-9NGTPcldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWPJR|UxRTR5Lkm1PFEh|ryPMUDTRW5ITVJ?
SK-N-FIMlPKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2fX[WlEPTB;NEiuNFM2QCEQvF2=MnLKV2FPT0WU
KALS-1NWn6WG9zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWTJR|UxRTR6LkGyPFkh|ryPMV7TRW5ITVJ?
HO-1-N-1MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Ml\yTWM2OD12OD63OFQ2KM7:TR?=NY\3dXVTW0GQR1XS
NCI-H2452M3z5NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVnQTIVtUUN3ME20PU4yOTV{IN88US=>NXXn[lhMW0GQR1XS
OC-314MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoDpTWM2OD12OT62PFM1KM7:TR?=NEfGenNUSU6JRWK=

... Click to View More Cell Line Experimental Data

In vivo When ABT-263 is administered at 100 mg/kg/day in the H345 xenograft model, significant antitumor efficacy is observed with 80% TGI and 20% of treated tumors indicating at least a 50% reduction in tumor volume. [2] Oral administration of ABT-263 alone causes complete tumor regressions in xenograft models of small-cell lung cancer and acute lymphoblastic leukemia. In xenograft models of aggressive B-cell lymphoma and multiple myeloma where ABT-263 displays modest or no single agent activity, it significantly enhances the efficacy of clinically relevant therapeutic regimens. [2]
Features

Protocol(Only for Reference)

Kinase Assay:

[1]

Affinity determination Binding affinities (Ki or IC50) of ABT-263 against different isoforms of Bcl-2 family are determined with competitive fluorescence polarization assays. The following peptide probe/protein pairs are used: f-bad (1 nM) and Bcl-xL (6 nM), f-Bax (1 nM) and Bcl-2 (10 nM), f-Bax (1 nM) and Bcl-w (40 nM), f-Noxa (2 nM) and Mcl-1 (40 nM), and f-Bax (1 nM) and Bcl-2-A1 (15 nM). Binding affinities for Bcl-xL are also determined using a time-resolved fluorescence resonance energy transfer assay. Bcl-xL (1 nM, His tagged) is mixed with 200 nM f-Bak, 1 nM Tb-labeled anti-His antibody, and ABT-263 at room temperature for 30 min. Fluorescence is measured on an Envision plate reader using a 340/35 nm excitation filter and 520/525 (f-Bak) and 495/510 nm (Tb-labeled anti-His antibody) emission filters.

Cell Assay:

[1]

Cell lines SCLC cell lines
Concentrations 0-1 μM
Incubation Time 48 hours
Method

Human tumor cell lines SCLC cell lines are maintained at 37 °C containing 5% CO2. SCLC cell lines are cultured in RPMI 1640 with 10% fetal bovine serum (FBS), 1% sodium pyruvate, 25 mM HEPES, 4.5 g/L glucose, and 1% penicillin/streptomycin. Leukemia and lymphoma cell lines are cultured in RPMI 1640 supplemented with 10% FBS and 1% penicillin/streptomycin. Cells (1-5×10 4) are treated by ABT-263 for 48 hours in 96-well culture plates in a final volume of 100 μL and cytotoxicity is assessed with the CellTiter Glo assay. In vitro cyto toxicity of ABT-263 is assayed.

Animal Study:

[1]

Animal Models C.B.-17 scid-bg or C.B.-17 scid mice
Formulation Formulated in 10% ethanol, 30% polyethylene glycol 400, and 60% Phosal 50 PG
Dosages 100 mg/kg/d
Administration Administered via p.o.

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)0.020.151.80.40.0810
Body Surface Area (m2)0.0070.0250.150.050.020.5
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] Tse C, et al. Cancer Res. 2008, 68(9), 3421-3428.

[2] Shoemaker AR, et al. Clin Cancer Res, 2008, 14(11), 3268-3277.

Clinical Trial Information( data from http://clinicaltrials.gov, updated on 2016-04-16)

NCT Number Recruitment Conditions Sponsor
/Collaborators
Start Date Phases
NCT02520778 Recruiting Recurrent Non-Small Cell Lung Carcinoma|Stage IIIA Non-Small Cell Lung Cancer|Stage IIIB Non-Small Cell Lung Cancer|Stage IV Non-Small Cell Lung Ca  ...more Recurrent Non-Small Cell Lung Carcinoma|Stage IIIA Non-Small Cell Lung Cancer|Stage IIIB Non-Small Cell Lung Cancer|Stage IV Non-Small Cell Lung Cancer National Cancer Institute (NCI) March 2016 Phase 1
NCT02591095 Recruiting Platinum-resistant or Refractory Ovarian Cancer Centre Francois Baclesse|ARCAGY/ GINECO GROUP|French Canc  ...more Centre Francois Baclesse|ARCAGY/ GINECO GROUP|French Cancer Research Hospital Program January 2016 Phase 2
NCT02143401 Recruiting Recurrent Hepatocellular Carcinoma|Solid Neoplasm|Stage IV Hepatocellular Carcinoma National Cancer Institute (NCI) November 2014 Phase 1
NCT02079740 Suspended Extensive Stage Small Cell Lung Carcinoma|Recurrent Colorectal Carcinoma|Recurrent Non-Small Cell Lung Carcinoma|Recurrent Pancreatic Carcinoma|Rec  ...more Extensive Stage Small Cell Lung Carcinoma|Recurrent Colorectal Carcinoma|Recurrent Non-Small Cell Lung Carcinoma|Recurrent Pancreatic Carcinoma|Recurrent Small Cell Lung Carcinoma|Solid Neoplasm|Stage III Pancreatic Cancer|Stage IIIA Colorectal Cancer|Stage IIIA Non-Small Cell Lung Cancer|Stage IIIB Colorectal Cancer|Stage IIIB Non-Small Cell Lung Cancer|Stage IIIC Colorectal Cancer|Stage IV Non-Small Cell Lung Cancer|Stage IV Pancreatic Cancer|Stage IVA Colorectal Cancer|Stage IVB Colorectal Cancer National Cancer Institute (NCI) March 2014 Phase 1|Phase 2
NCT01989585 Suspended Metastatic Melanoma|Recurrent Melanoma|Solid Neoplasm|Stage IIIA Skin Melanoma|Stage IIIB Skin Melanoma|Stage IIIC Skin Melanoma|Stage IV Skin Mela  ...more Metastatic Melanoma|Recurrent Melanoma|Solid Neoplasm|Stage IIIA Skin Melanoma|Stage IIIB Skin Melanoma|Stage IIIC Skin Melanoma|Stage IV Skin Melanoma National Cancer Institute (NCI) October 2013 Phase 1|Phase 2

view more

Chemical Information

Download ABT-263 (Navitoclax) SDF
Molecular Weight (MW) 974.61
Formula

C47H55ClF3N5O6S3

CAS No. 923564-51-6
Storage 3 years -20℃powder
6 months-80℃in solvent
Synonyms N/A
Solubility (25°C) * In vitro DMSO 100 mg/mL (102.6 mM)
Water <1 mg/mL (<1 mM)
Ethanol <1 mg/mL (<1 mM)
In vivo
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name 4-​[4-​[[2-​(4-​chlorophenyl)​-​5,​5-​dimethyl-​1-​cyclohexen-​1-​yl]​methyl]​-​1-​piperazinyl]​-​N-​[[4-​[[(1R)​-​3-​(4-​morpholinyl)​-​1-​[(phenylthio)​methyl]​propyl]​amino]​-​3-​[(trifluoromethyl)​sulfonyl]​phenyl]​sulfonyl]​-benzamide

Customer Product Validation (13)


Click to enlarge
Rating
Source J Clin Invest, 2014, 124(1): 117-28 . ABT-263 (Navitoclax) purchased from Selleck
Method Cell Viability Analysis
Cell Lines KP cells & A549 cells
Concentrations 300、500 nM
Incubation Time 96 h
Results KP mouse and A549 cells treated with a combination of ATN-224 and ABT-263 showed an increase in cell death compared with cells treated with ATN-224 alone.

Click to enlarge
Rating
Source Cell Death Differ, 2015, 10.1038/cdd.2015.73. ABT-263 (Navitoclax) purchased from Selleck
Method Cell Viability Analysis
Cell Lines NSC & Mcl-1 cells
Concentrations
Incubation Time 5 d
Results As seen with ABT-263, cells were largely resistant to compound alone but were extremely sensitive to combination with Mcl-1 silencing. In summary, the Bcl-xL inhibitors ABT-263 and WEHI-539 have an additive effect with Mcl-1 knockdown to reduce cell viabi眏Ỵ眐㠞眎膉癠 

Click to enlarge
Rating
Source Clin Cancer Res 2010 16, 4217-4225. ABT-263 (Navitoclax) purchased from Selleck
Method Fluorescence polarization assay
Cell Lines
Concentrations 0.1-10 μmol/L
Incubation Time 4-12 h
Results To further characterize the nature of the binding of ABT-737 and ABT-263 to albumin, we used a fluorescence polarization assay.There are two main drug-binding sites on HSA: site 1 on subdomain IIA and site 2 on subdomain IIIA.Interestingly, ABT-263 displayed a markedly higher binding affinity to site 2 on HSA-III A than did ABT-737 (Fig. A). Whereas ABT-737 showed no binding to site 1, ABT-263 also bound to site 1 on HSA-IIA with an IC50 of 145 μmol/L (positive control phenylbutazone: 49 μmol/L; ref. 18; Fig. B) . These data show that ABT-263 has a higher albumin-binding capacity than does ABT-737, thus limiting the amount of free drug that is available to interact with the intended target, BCL2.

Click to enlarge
Rating
Source Clin Cancer Res 2010 16, 4217-4225. ABT-263 (Navitoclax) purchased from Selleck
Method Fluorescein-dextran release assay/western blot
Cell Lines CLL cells
Concentrations 0-5 μmol/L
Incubation Time 1-2.5 h
Results One possible explanation for the reduced potency of ABT-263 compared with ABT-737 could be due to the former being inherently less potent. To investigate this possibility we compared their activities in a model biochemical system, using liposomes loaded with fluorescein-conjugated 10 kD dextran.The BCL-XL-mediated inhibition of liposome permeabilization was reversed in an a lmost identical concentration-dependent manner by both ABT-263 and ABT-737 (Fig. A). These results showed that both ABT-263 and ABT-737 targe t antiapoptotic BCL-XL with similar efficiency in this model liposome system containing only BCL2 family members but devoid of extraneous proteins. Another explanation for the lower potency of ABT-263 could be a lower plasma membrane permeability.we investigated the potential of ABT-737 and ABT-263 to induce cytochromec release from permeabilized CLL cells(Fig. B). ABT-737 was clearly more potentin inducing cytochrome c release from permeabilized cells.Taken together these results indicate that the reduced potential of ABT-263 to induce apoptosis cannot be explained solely by either differential plasma membrane permeability or by a lower potency of ABT-263 compared with ABT-737 to inhibit antiapoptotic BCL2 family members.

Click to enlarge
Rating
Source Clin Cancer Res 2010 16, 4217-4225. ABT-263 (Navitoclax) purchased from Selleck
Method Mitochondrial membrane potential assay/Immunoprecipitation/electron microscopy/apoptosis assays
Cell Lines CLL cells/murine embryonic fibroblasts
Concentrations 10-100 nmol/L/0.3-30 μmol/L
Incubation Time 2-48 h
Results To gain in sight into the mechanism of ABT-263-induced cell death, we asked whether ABT-263 induced activation of apoptotic signaling pathways. ABT-263 induced a rapid cleavage of caspase-3 and loss of mitochondrial membrane potential, but was a gain less potent than ABT-737 ( Fig.A).To investigate the activity of both compounds at the level of BCL2 inhibition, we immunoprecipitated BCL2 upon drug treatment and measured the levels of BAK displaced by ABT-737 and ABT-263.BAK was shown to be associated with BCL2 (Fig. B). ABT-737 (10 or 100 nmol/L) efficiently d isplaced BAK from BCL2, whereas higher concentrations of ABT-263 (100 nmol /L) were required to induce release of BAK (Fig. B).ABT-263 (100 nmol/L) induced similar ultrastructural changes to ABT-737 (10 nmol/L), including condensed chromatin, rupture of the outer mitochondrial membrane, and loss of mitochondrial matrix d ensity (Fig. C).Finally, ABT-263-induced apoptosis was compl et ely inhibited in murine embryonic fibroblasts deficient for Bax and Bak (Fig. D), suggesting that ABT-263, like ABT-737 is a specific inhibitor of BCL2 proteins.

Click to enlarge
Rating
Source Clin Cancer Res 2010 16, 4217-4225. ABT-263 (Navitoclax) purchased from Selleck
Method Apoptosis assays
Cell Lines CLL cells
Concentrations 1-1000 nmol/L
Incubation Time 4 h
Results In our study we identify two factors that affect the efficacy of the ABT-263: high cell density and plasma protein binding. In leukemic patients, the high circulating cell densities might contribute to the resistance of CLL cells to ABT-263 that we observed in whole blood as compared with standard cell culture (Fig. B).We also describe that the ABT-263 is extensively bound to albumin and that in the presence of albumin higher drug concentrations are required for apoptosis induction (Fig. D)

Click to enlarge
Rating
Source Clin Cancer Res 2010 16, 4217-4225. ABT-263 (Navitoclax) purchased from Selleck
Method Apoptosis assays
Cell Lines CLL cells
Concentrations 1-1000 nmol/L
Incubation Time 4 h
Results We compared the in vitro efficacy of two very closely related BCL2 antagon ists, ABT-737 and ABT-263. A direct comparison of the susceptibility of freshly isolated CLL cells to ABT-737 and ABT-263 in RPMI supplemented with 10% FCS revealed that both compounds induced efficient apoptosis but ABT-737 was∼4-fold more potent.

Click to enlarge
Rating
Source PLoS One 2011 6, e21980. ABT-263 (Navitoclax) purchased from Selleck
Method Hoechst staining/western blot
Cell Lines LH86 cells/Huh7 cells
Concentrations 0–20 μM
Incubation Time 24 h
Results The higher dose of ABT-263 (10–20 μM) treatment for 24 h induced significant DNA fragmentation and caspase 9 or 3 cleavage activation in HCC cells, whereas lower concentrations of ABT-263 (0–2.5 μM) had no apoptotic toxicity to HCC cells. These results suggest that HCC cells are relatively resistant to low doses of ABT-263.

Click to enlarge
Rating
Source PLoS One 2011 6, e21980. ABT-263 (Navitoclax) purchased from Selleck
Method Western blot/Hoechst staining/Apoptosis assays
Cell Lines LH86 cells
Concentrations 1 μM
Incubation Time 1-6 h
Results As shown in Figure A, the combination treatment of HCC cells with ABT-263 (1 μM) and YM-155 (1μM) for up to 6 h has no effects on the expressions of either anti-apoptotic protein Bcl-xL or pro-apoptotic proteins including Bad, Bak, and Bax. However, as expected, the presence of YM-155 significantly decreased survivin protein expression (Figure B, left third lane). Co-treatment of cells with ABT-263 (1 μM) and YM-155 (1μM) induced an even greater decrease in survivin protein expression (Figure B, right two lanes) than that of YM-155 itself did. However, we indeed observed that ABT-263 single treatment for 3 h resulted in survivin increase (Figure B). To further determine survivin inhibition plays a critical role in sensitizing ABT-263 to induce apoptosis in HCC cells, we down-regulated survivin expression in HCC cells by siRNA duplexes targeted against human survivin mRNA, and then examined the expression of survivin by Western blotting (Figure C) and apoptotic events after ABT-263 treatments. The results demonstrated that ABT-263 induced significant apoptosis in the survivin siRNA-transfected cells, but not in siRNA Random-transfected (control) cells (Figure D, E, and F).

Click to enlarge
Rating
Source PLoS One 2011 6, e21980. ABT-263 (Navitoclax) purchased from Selleck
Method Western blot/Hoechst staining
Cell Lines LH86 cells
Concentrations 1-2.5 μM
Incubation Time 1-24 h
Results Treatment of cells with ABT-263 (1-2.5 μM) for 1 h could result in the increase of phosphorylated ERK (p-ERK) but not ERK (Figure A). On the other hand, as shown in Figure B, ABT-263 (1 μM) administration could result in survivin expression increase. Thus, in an attempt to know if ERK-survivin activation could protect cells against ABT-263 toxicity, cells were untreated or treated with ABT-263 (1 μM), PD98059 (50 μM), or pre-treated with PD98059 (50 μM) followed by ABT-263 (1 μM). As shown in Figure C and D, blocking ERK activation with specific inhibitor PD98059 enhanced ABT-263-indcued apoptosis in HCC cells. To further determine ERK anti-apoptotic effects on ABT-263 treated HCC cells, we knocked down ERK expression through siRNA mediated gene silencing (Figure E) and then administrated ABT-263. Similar results revealed that ERK depletion sensitized ABT-263-induced apoptosis (Figure F). These results suggest the activation of ERK-survivin may render cells to be resistant to low dose ABT-263-induced apoptosis.

Click to enlarge
Rating
Source Biochem Biophys Res Commun 2011 408(2), 344-9. ABT-263 (Navitoclax) purchased from Selleck
Method Flow cytometry
Cell Lines MDCKII wild type cells/MDR1 cells
Concentrations 50 nM
Incubation Time 24 h
Results MDCKII cells transfected with MDR1 showed significantly less apoptosis inducedby ABT-737 (Fig. C) and ABT-263 (Fig. D) than wild type cells.

Click to enlarge
Rating
Source ABT-263 (Navitoclax) purchased from Selleck
Method Western Blotting/Co-Immunoprecipitation / Cell Death Experiments
Cell Lines Arf -null p185+ cells/ p185+ Arf-/- cells
Concentrations 0-1000nM
Incubation Time 24 h
Results As the navitoclax dose increased the amount of BCL-2 and BCL-X L immunoprecipitating with BIM decreased and there was a corresponding increase in MCL-1 protein associated with BIM (Fig. B). These data indicated that navitoclax displaced BIM from BCL-2 and BCL-XL and suggests that the liberated BIM could then interact with MCL-1 (Fig. B). As the navitoclax was increased we observed potentiation of the TKIs indicating a synergistic effect of combining navitoclax and TKI treatment (Fig. E&F).

Click to enlarge
Rating
Source ABT-263 (Navitoclax) purchased from Selleck
Method Western Blotting/Co-Immunoprecipitation / Cell Death Experiments
Cell Lines OP-1 Ph+ B-ALL cells/TOM1 Ph+ B-ALL cells/BV173 Ph+CML cells
Concentrations 0-60 nM
Incubation Time 24 h
Results As navitoclax was increased in the cultures we observed a potentiation of the TKIs to induce apoptosis. These data indicate that like our bservations in mouse BCR-ABL cell lines, combining TKIs and navitoclax in human Ph+ cell lines can also lead to enhanced activity. While MCL-1 expression is most overtly decreased in response to TKI treatment, it is possible that combining TKI and navitoclax may effect targets other than MCL-1 leading to cell death. These data suggest that combining TKIs and navitoclax may be effective in treating human Ph+ leukemia.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related Bcl-2 Products

  • A-1210477

    A-1210477 is a potent and selective MCL-1 inhibitor with Ki and IC50 of 0.454 nM and 26.2 nM, respectively, >100-fold selectivity over other Bcl-2 family members.

  • MI-773 (SAR405838)

    MI-773 (SAR405838) is an orally available MDM2 antagonist with Ki of 0.88 nM. Phase 1.

  • Venetoclax (ABT-199, GDC-0199)

    Venetoclax (ABT-199, GDC-0199) is a Bcl-2-selective inhibitor with Ki of <0.01 nM in cell-free assays, >4800-fold more selective versus Bcl-xL and Bcl-w, and no activity to Mcl-1. Phase 3.

    Features:Re-engineered version of ABT-263 (Navitoclax).

  • ABT-737

    ABT-737 is a BH3 mimetic inhibitor of Bcl-xL, Bcl-2 and Bcl-w with EC50 of 78.7 nM, 30.3 nM and 197.8 nM in cell-free assays, respectively; no inhibition observed against Mcl-1, Bcl-B or Bfl-1. Phase 2.

  • UMI-77

    UMI-77 is a selective Mcl-1 inhibitor with Ki of 490 nM, showing selectivity over other members of Bcl-2 family.

  • Obatoclax Mesylate (GX15-070)

    Obatoclax Mesylate (GX15-070) is an antagonist of Bcl-2 with Ki of 0.22 μM in a cell-free assay, can assist in overcoming MCL-1 mediated resistance to apoptosis. Phase 3.

    Features:Potential 1st-in-class small molecule antagonist of Bcl-2 designed to inhibit all relevant Bcl-2 family members, including Mcl-1.

  • TW-37

    TW-37 is a novel nonpeptide inhibitor to recombinant Bcl-2, Bcl-xL and Mcl-1 with Ki of 0.29 μM, 1.11 μM and 0.26 μM in cell-free assays, respectively.

  • Sabutoclax

    Sabutoclax(BI-97C1) is a pan-Bcl-2 inhibitor, including Bcl-xL, Bcl-2, Mcl-1 and Bfl-1 with IC50 of 0.31 μM, 0.32 μM, 0.20 μM and 0.62 μM, respectively.

  • AT101

    AT101, the R-(-) enantiomer of Gossypol acetic acid, binds with Bcl-2, Bcl-xL and Mcl-1 with Ki of 0.32 μM, 0.48 μM and 0.18 μM in cell-free assays; does not inhibit BIR3 domain and BID. Phase 2.

Recently Viewed Items

Tags: buy ABT-263 (Navitoclax) | ABT-263 (Navitoclax) supplier | purchase ABT-263 (Navitoclax) | ABT-263 (Navitoclax) cost | ABT-263 (Navitoclax) manufacturer | order ABT-263 (Navitoclax) | ABT-263 (Navitoclax) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Contact Us